Skip to main content
Top
Published in: International Ophthalmology 3/2012

01-06-2012 | Case Report

The mystery of angiographically silent macular oedema due to taxanes

Authors: Tatiana I. Kuznetcova, Petr Cech, Carl P. Herbort

Published in: International Ophthalmology | Issue 3/2012

Login to get access

Abstract

Taxanes are widely used anticancer agents, produced from the plants of the genus Taxus (yews). One of the rare side-effects caused by taxanes is a bilateral cystoid macular oedema (CMO). The particularity of this type of CMO is that it is angiographically silent showing no leakage or pooling on fluorescein angiography (FA). To date, the mechanism of this oedema has not been clearly understood and existing theories do not explain this phenomenon very well. Our aim was to report a case of paclitaxel-induced CMO and put forward a putative explanation for this occurrence. A 64-year-old woman presented with a 7-month history of progressively decreasing bilateral visual acuity with an apparently normal fundus. At entry her best-corrected visual acuity (BCVA) was 0.4 for far and near OD and 0.5 for far and near OS. Optical coherence tomography (OCT) revealed a CMO with a central thickness of 561 μm OD and 488 μm OS; there were no signs of intraocular inflammation. FA showed no capillary leakage and quasi absent late hyperfluorescence OU. Indocyanine green angiography was within normal limits. Classical CMO treatment was ineffective and only discontinuation of paclitaxel resulted in recovery of a normal macular structure after 4 weeks with an increase of BCVA to 0.9 OD and 1.0 OS. In order to understand the properties of taxane drug-induced cystoid macular oedema (TDICMO) we compared the spectral OCT findings of our case to an inflammation-induced CMO of equal thickness and to a case of multifocal choroiditis. The plane of separation of TDICMO was above the external limiting membrane in both cases. In contrast to inflammation-induced CMO where the four external bands were well identified, there was attenuation of these bands in TDICMO but no disruption of the layers as seen in multifocal choroiditis, indicating that the fluid in TDICMO had a high viscosity producing a shadow underneath. TDICMO most probably originates from retinal pigment epithelium dysfunction by their effect on microtubule functions and not from vascular leakage. The content of the CMO seems to be made up of viscous fluid. As the origin of the CMO is not inflammatory, classical CMO treatments have no effect and only discontinuation of the taxane drug allows reversal of the CMO.
Literature
1.
go back to reference Crown J, Leary MO, Ooi WS (2004) Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 9:24–32PubMedCrossRef Crown J, Leary MO, Ooi WS (2004) Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 9:24–32PubMedCrossRef
2.
go back to reference Eisner A, Luoh SW (2011) Breast cancer medications and vision: effects of treatments for early-stage disease. Curr Eye Res 36:867–885PubMed Eisner A, Luoh SW (2011) Breast cancer medications and vision: effects of treatments for early-stage disease. Curr Eye Res 36:867–885PubMed
3.
go back to reference Teitelbaum BA, Tresley DJ (2003) Cystic maculopathy with normal capillary permeability secondary to docetaxel. Optom Vis Sci 80:277–279PubMedCrossRef Teitelbaum BA, Tresley DJ (2003) Cystic maculopathy with normal capillary permeability secondary to docetaxel. Optom Vis Sci 80:277–279PubMedCrossRef
4.
go back to reference Behar A, Lauraine EP, Maurel A, Brun MD, Lagrue G, Chauvin FF, Oulid-Aissa D, Hille D (1997) The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. Br J Clin Pharmacol 43:653–658PubMedCrossRef Behar A, Lauraine EP, Maurel A, Brun MD, Lagrue G, Chauvin FF, Oulid-Aissa D, Hille D (1997) The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. Br J Clin Pharmacol 43:653–658PubMedCrossRef
5.
go back to reference Semb KA, Aamdal S, Oian P (1998) Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 16:3426–3432PubMed Semb KA, Aamdal S, Oian P (1998) Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 16:3426–3432PubMed
6.
go back to reference Smith SV, Matthew BA, Benz S, Brown DM (2008) Cystoid macular edema secondary to albumin-bound paclitaxel therapy. Arch Ophthalmol 126:1605–1606PubMedCrossRef Smith SV, Matthew BA, Benz S, Brown DM (2008) Cystoid macular edema secondary to albumin-bound paclitaxel therapy. Arch Ophthalmol 126:1605–1606PubMedCrossRef
8.
go back to reference Bringmann A, Reichenbach A, Wiedemann P (2004) Pathomechanisms of cystoid macular edema. Ophthalmic Res 36:241–249PubMedCrossRef Bringmann A, Reichenbach A, Wiedemann P (2004) Pathomechanisms of cystoid macular edema. Ophthalmic Res 36:241–249PubMedCrossRef
9.
10.
go back to reference Telander DG, Sarraf D (2007) Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome. Semin Ophthalmol 22:151–153PubMedCrossRef Telander DG, Sarraf D (2007) Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome. Semin Ophthalmol 22:151–153PubMedCrossRef
11.
go back to reference Karakashian S, Bayliff CD (2001) Niacin-induced cystoid macular edema. CJHP 54:35–36 Karakashian S, Bayliff CD (2001) Niacin-induced cystoid macular edema. CJHP 54:35–36
12.
go back to reference Dajani HM, Lauer AK (2006) Optical coherence tomography findings in niacin maculopathy. Can J Ophthalmol 41:197–200PubMedCrossRef Dajani HM, Lauer AK (2006) Optical coherence tomography findings in niacin maculopathy. Can J Ophthalmol 41:197–200PubMedCrossRef
13.
go back to reference Michaud LB, Valero V, Hortobagyi G (2000) Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf 23:401–428PubMedCrossRef Michaud LB, Valero V, Hortobagyi G (2000) Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf 23:401–428PubMedCrossRef
14.
go back to reference Mitchison TJ (1992) Compare and contrast actin filaments and microtubules. Mol Biol Cell 3:1309–1315PubMed Mitchison TJ (1992) Compare and contrast actin filaments and microtubules. Mol Biol Cell 3:1309–1315PubMed
15.
go back to reference Burnside B, Bost-Usinger L (1998) The retinal pigment epithelium cytoskeleton. In: Marmor MF, Wolfensberger TJ (eds) The retinal pigment epithelium. Oxford University Press, New York, pp 41–67 Burnside B, Bost-Usinger L (1998) The retinal pigment epithelium cytoskeleton. In: Marmor MF, Wolfensberger TJ (eds) The retinal pigment epithelium. Oxford University Press, New York, pp 41–67
Metadata
Title
The mystery of angiographically silent macular oedema due to taxanes
Authors
Tatiana I. Kuznetcova
Petr Cech
Carl P. Herbort
Publication date
01-06-2012
Publisher
Springer Netherlands
Published in
International Ophthalmology / Issue 3/2012
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI
https://doi.org/10.1007/s10792-012-9558-9

Other articles of this Issue 3/2012

International Ophthalmology 3/2012 Go to the issue